文献速递其他结缔组织病

Nerandomilast通过调控非Smad信号通路并激活cAMP-PKA-RhoA通路缓解肌炎相关间质性肺病

Nerandomilast alleviates myositis-associated interstitial lung disease by modulating the non-Smad signalling pathway and activating the cAMP-PKA-RhoA pathway.
PubMed 文献 · RMD Open · 2026-05-07

该研究在肌炎相关间质性肺病(IIM-ILD)小鼠模型和人肺微血管内皮细胞中探究PDE4B抑制剂nerandomilast(BI 1015550)的作用及机制。结果显示BI 1015550减轻肺部炎症和纤维化评分、降低炎症因子、减少NET形成并抑制内皮间质转化,且无肝肾毒性。

要点

  • IIM-ILD患者和小鼠肺组织中PDE4B表达上调。
  • BI 1015550减轻模型小鼠肺部炎症和纤维化,无肝肾毒性。
  • 机制涉及抑制NET形成、内皮间质转化及非Smad通路调控。

核心结论

  • Nerandomilast通过抑制NET形成和内皮间质转化缓解IIM-ILD,可能涉及非Smad信号通路调节和cAMP-PKA-RhoA通路激活。
  • 特异性抑制PDE4B可能是IIM-ILD的潜在治疗策略。

研究设计与样本

  • 采用肌炎相关间质性肺病小鼠模型给予nerandomilast(BI 1015550)处理,并进行肺组织病理学评估。
  • 体外用人肺微血管内皮细胞-5a经中性粒细胞胞外诱捕网刺激诱导内皮间质转化。
  • 采用Western blotting、免疫荧光、qPCR和ELISA分析通路和细胞因子。

主要发现

  • PDE4B在IIM-ILD患者肺组织和小鼠肺组织中表达上调。
  • BI 1015550显著降低肺炎症和纤维化评分,减少支气管肺泡灌洗液和血清中炎症细胞因子。
  • BI 1015550减轻肌肉炎症并降低激酶活性,且无明显肝肾毒性。
  • 免疫荧光和免疫组化显示NET标志物减少、炎症细胞浸润(CD3、CD11b、F4/80)减轻、内皮间质转化受抑。
  • BI 1015550下调RhoA并抑制关键纤维化通路:P-PI3K、P-AKT、P-P38、P-ERK、P-NF-κB。

关键数值与推荐

  • 体外实验中BI 1015550抑制佛波酯诱导的中性粒细胞胞外诱捕网形成和内皮间质转化。

临床怎么用

  • PDE4B抑制可能作为IIM-ILD的潜在治疗方向,需进一步临床验证。

局限性

  • 研究主要基于小鼠模型和体外细胞实验,尚需临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Nerandomilast, a selective phosphodiesterase 4B (PDE4B) inhibitor, has been extensively investigated for the treatment of pulmonary fibrosis; however, its therapeutic potential and mechanisms of action in idiopathic inflammatory myopathies-associated interstitial lung disease (IIM-ILD) remain to be elucidated. METHODS: A myositis-associated ILD mouse model was treated with nerandomilast (BI 1015550), and lung pathology was assessed histologically. Human lung microvascular endothelial cells-5a were stimulated with neutrophil extracellular traps (NETs) to induce endothelial-mesenchymal transition (EndMT). Western blotting, immunofluorescence, qPCR and ELISA were employed to analyse pathways and cytokines. RESULTS: PDE4B was upregulated in the lungs of patients with IIM-ILD and in mice. Treatment with BI 1015550 significantly reduced lung inflammation and fibrosis scores, decreased inflammatory cytokines in bronchoalveolar lavage fluid and serum, alleviated muscle inflammation and lowered kinase activity without evident hepatorenal toxicity. Immunofluorescence and immunohistochemistry revealed diminished NET markers, reduced inflammatory cell infiltration (CD3, CD11b, F4/80), suppression of EndMT, downregulation of Ras homolog family member A (RhoA) and inhibition of key fibrotic pathways: phosphorylated phosphoinositide 3-kinase (P-PI3K), phosphorylated protein kinase B (P-AKT), phosphorylated p38 mitogen-activated protein kinase (P-P38), phosphorylated extracellular signal-regulated kinase (P-ERK), phosphorylated nuclear factor kappa-B (P-NF-κB). In vitro, BI 1015550 inhibited phorbol 12-myristate 13-acetate-induced neutrophil extracellular trap formation (NETosis) and EndMT. CONCLUSIONS: Nerandomilast alleviates IIM-ILD by inhibiting NET formation and suppressing EndMT in lung microvascular endothelial cells, potentially through non-Smad signalling pathway modulation and cAMP-PKA-RhoA pathway activation. These findings suggest that the specific inhibition of PDE4B is a potential therapeutic approach for IIM-ILD.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Cui X, Li W, Chai H, et al. Nerandomilast alleviates myositis-associated interstitial lung disease by modulating the non-Smad signalling pathway and activating the cAMP-PKA-RhoA pathway. RMD Open. 2026. PMID: 42097695. doi:10.1136/rmdopen-2025-006683

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。